XBiotech Inc. (XBIT) Sunk to $8.66

XBiotech Inc. (NASDAQ:XBIT) Corporate Logo

XBiotech Inc. (NASDAQ:XBIT) decreased considerably to $8.66. On Feb, 16 it was announced by Barchart.com. The company has $310.20M market cap. The company’s valuation will be $24.82 million less at $7.97 PT.

For more XBiotech Inc. (NASDAQ:XBIT) news announced briefly go to: Benzinga.com, Benzinga.com, Nasdaq.com, Benzinga.com or Globenewswire.com. The titles are as follows: “50 Biggest Movers From Yesterday – Benzinga” announced on February 06, 2019, “Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering – Benzinga” on February 06, 2019, “Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting – Nasdaq” with a publish date: January 28, 2019, “Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut – Benzinga” and the last “Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain – GlobeNewswire” with publication date: January 23, 2019.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases.The company has $310.20 million market cap. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.Currently it has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *